Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Localized morphea in children.

B R Krafchik1

  • 1Hospital for Sick Children, Department of Dermatology, Toronto, Ontario, Canada.

Advances in Experimental Medicine and Biology
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo.

The British journal of dermatology·2011
Same author

Acne.

Paediatrics & child health·2010
Same author

Eczema.

Paediatrics & child health·2010
Same author

Inflammatory linear verrucous epidermal nevus and arthritis: a new association.

The Journal of pediatrics·2001
Same author

Children with morphea have normal self-perception.

The Journal of pediatrics·2000
Same author

Vulvitis circumscripta plasmacellularis mimicking child abuse.

Journal of the American Academy of Dermatology·2000
Same journal

Mammalian Respiratory Chain Complex Assemblies and Their Links to Mitochondria Stress-Induced Human Diseases.

Advances in experimental medicine and biology·2026
Same journal

Enzyme Assemblies in Nucleotide Metabolism: Structure, Regulation, and Disease Implications.

Advances in experimental medicine and biology·2026
Same journal

The Pyruvate Dehydrogenase Complex: A 90-Year-Old Enigma Shaping the Future of Structural Enzymology.

Advances in experimental medicine and biology·2026
Same journal

Regulation of the Anti-termination RNA Transcription Complex by Lon-Mediated Lambda N Degradation.

Advances in experimental medicine and biology·2026
Same journal

PCNA Macromolecular Complexes: PCNA Serves as a Molecular Hub Regulating Multiple Cellular Processes Inside and Outside of the Nucleus.

Advances in experimental medicine and biology·2026
Same journal

Dynamic Assemblies in Genome Maintenance.

Advances in experimental medicine and biology·2026
See all related articles

Researchers are studying 60 patients with morphea and linear scleroderma, noting varied lesion depths and involvement of deeper tissues. Current treatment involves methotrexate and pulsed steroids, but evaluating effectiveness is challenging due to inconsistent cure times.

Area of Science:

  • Dermatology
  • Rheumatology
  • Pediatric Autoimmune Diseases

Background:

  • Morphea and linear scleroderma are inflammatory connective tissue diseases affecting the skin and potentially deeper tissues.
  • Lesion presentation in these conditions is highly variable, ranging from epidermal changes to involvement of subcutaneous tissue, muscle, and bone.
  • The lack of clear clinical markers and variable disease duration complicate treatment efficacy assessment.

Purpose of the Study:

  • To follow a cohort of pediatric patients diagnosed with morphea and/or linear scleroderma.
  • To characterize the clinical presentation and disease progression in affected children.
  • To evaluate the current treatment regimens for morphea and linear scleroderma in a pediatric population.

Main Methods:

Related Experiment Videos

  • Prospective observational study of 60 pediatric patients with morphea and/or linear scleroderma.
  • Clinical assessment of lesion depth and tissue involvement (epidermal, dermal, subcutaneous, muscle, bone).
  • Current treatment protocol includes weekly methotrexate (oral or subcutaneous) and monthly pulsed corticosteroids for three months.

    • Main Results:

    • The study cohort consists of 60 pediatric patients with morphea and/or linear scleroderma.
    • Observed variability in lesion depth, from epidermal changes similar to lichen sclerosis to deep dermal and subcutaneous involvement.
    • Involvement of underlying muscle and bone was noted in some cases.
    • No definitive clinical marker for disease activity or progression has been identified.
    • Significant variation in time to cure complicates the evaluation of treatment regimens.

    Conclusions:

    • Morphea and linear scleroderma in children present with diverse clinical manifestations and varying depths of tissue involvement.
    • The current treatment approach utilizes methotrexate and pulsed steroids, but its effectiveness is difficult to ascertain due to inconsistent patient outcomes and disease duration.
    • Further research is needed to identify reliable clinical markers and optimize treatment strategies for pediatric morphea and linear scleroderma.